Asthma Drug Fluticasone Fails as Potential COVID-19 Treatment

THURSDAY, July 14, 2022 (HealthDay News) -- The asthma drug fluticasone furoate is yet another medication that does not work for mild-to-moderate COVID-19, a new study finds. The study was published online July 13 in medRxiv, which publishes studies before they have been peer-reviewed.
"There was no evidence of improvement in time to recovery or reduction in hospitalizations in participants who took fluticasone furoate versus those who took a placebo," lead researcher Adrian Hernandez, M.D., executive director of the Duke Clinical Research Institute in Durham, North Carolina, said in a Duke news release.
The finding comes from a nationwide study of nearly 5,000 participants that continues to evaluate the potential benefit of existing drugs to treat mild-to-moderate COVID-19. Fluticasone furoate is one of three U.S. Food and Drug Administration-approved repurposed medications currently being tested against COVID-19.
Fluticasone furoate is an inhaled corticosteroid used to treat asthma, but it is not approved to treat COVID-19. This drug was tested because corticosteroids had seemed potentially beneficial for treating COVID-19 among nonhospitalized patients. Based on the findings, fluticasone furoate should not be used to treat COVID-19, the researchers stressed.
Abstract/Full Text (subscription or payment may be required)
Related Posts
Una disección en la aorta, una arteria del corazón, con frecuencia es letal, pero la supervivencia mejora
VIERNES, 16 de septiembre de 2022 (HealthDay News) -- Una disección (desgarro)...
Añadir estos alimentos a su dieta podría mantener a la demencia a raya
JUEVES, 5 de mayo de 2022 (HealthDay News) -- Una dieta rica en los...
Most Eutylone-Involved Deaths in 2020 Occurred in Two States
THURSDAY, Aug. 11, 2022 (HealthDay News) -- Most eutylone-involved deaths in...
